Ora Rosengarten

TL;DR: Responses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations, and warrants further investigation in confirmatory studies.

TL;DR: Following ≥3 prior lines of chemotherapy, olaparib 400mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer and no new safety signals were identified.

TL;DR: While the PK of PLD is not dose-dependent within the dose range of 30–60 mg/m2, there is evidence of a cycle-dependent effect that results in inhibition of clearance when patients receive successive cycles ofPLD.

TL;DR: The findings support using endocrine therapy alone in ER+ HER2-negative breast cancer patients with micrometastases/1–3 positive nodes and Recurrence Score < 18 and suggest that only women with OncotypeDX scores under 18 can forgo chemotherapy.

TL;DR: In chemotherapy-untreated patients with RS 11–25 (where TAILORx patients were randomized to chemoendocrine or endocrine therapy alone), 5-year distant recurrence rates were very low, suggesting that chemotherapy would not have conferred clinically meaningful benefit, and the results extend those of the prospective TAILorx trial.